These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32792853)

  • 21. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
    Freiser ME; Serafini P; Weed DT
    Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanovaccines for cancer immunotherapy.
    Zhang Y; Lin S; Wang XY; Zhu G
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for head and neck cancer patients: shifting the balance.
    Turksma AW; Braakhuis BJ; Bloemena E; Meijer CJ; Leemans CR; Hooijberg E
    Immunotherapy; 2013 Jan; 5(1):49-61. PubMed ID: 23256798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunotherapy for head and neck squamous cell carcinoma].
    Chen J; Chen M; Wu HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head and neck cancer immunotherapy: clinical evaluation.
    Leibowitz MS; Nayak JV; Ferris RL
    Curr Oncol Rep; 2008 Mar; 10(2):162-9. PubMed ID: 18377830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunology and Immunotherapy of Head and Neck Cancer.
    Ferris RL
    J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapy for HNSCC : Quo vadis?].
    Döscher J; Busch CJ; Schuler PJ; Laban S
    HNO; 2016 Oct; 64(10):700-7. PubMed ID: 27624904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune alterations and immunotherapy prospects in head and neck cancer.
    Varilla V; Atienza J; Dasanu CA
    Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
    Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
    Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for head and neck cancer.
    Davidson HC; Leibowitz MS; Lopez-Albaitero A; Ferris RL
    Oral Oncol; 2009 Sep; 45(9):747-51. PubMed ID: 19442565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck.
    Hoffmann TK; Bier H; Whiteside TL
    Cancer Immunol Immunother; 2004 Dec; 53(12):1055-67. PubMed ID: 15095020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
    von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
    Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
    Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
    Voskens CJ; Sewell D; Hertzano R; DeSanto J; Rollins S; Lee M; Taylor R; Wolf J; Suntharalingam M; Gastman B; Papadimitriou JC; Lu C; Tan M; Morales R; Cullen K; Celis E; Mann D; Strome SE
    Head Neck; 2012 Dec; 34(12):1734-46. PubMed ID: 22287423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for head and neck cancer: advances and deficiencies.
    De Costa AM; Young MR
    Anticancer Drugs; 2011 Aug; 22(7):674-81. PubMed ID: 21037467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.
    Schutt C; Bumm K; Mirandola L; Bernardini G; Cunha N; Tijani L; Nguyen D; Cordero J; Jenkins MR; Cobos E; Kast WM; Chiriva-Internati M
    Int Rev Immunol; 2012 Feb; 31(1):22-42. PubMed ID: 22251006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapeutics for head and neck squamous cell carcinoma stem cells.
    Qian X; Leonard F; Wenhao Y; Sudhoff H; Hoffmann TK; Ferrone S; Kaufmann AM; Albers AE
    HNO; 2020 Feb; 68(2):94-99. PubMed ID: 31996933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials.
    Browder JP; Chretien PB
    Semin Oncol; 1977 Dec; 4(4):431-9. PubMed ID: 339354
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.